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were not significantly different on MDD-related outpatient services (least-squares 
mean difference[95% CI] for number of outpatient visits: 0.31[-0.01, 0.64]; OR[95% 
CI] for having ≥ 2 outpatient visits: 1.04[0.82, 1.32] for SNRI vs SSRI). ConClusions: 
Chinese physicians seem more likely to choose SNRI than SSRI for the treatment of 
severely-ill MDD patients, as suggested by the patients’ higher likelihood of being 
treated at mental hospitals and having more MDD-related outpatient visits pre-
medication initiation. Although SNRI initiators may be more severely-ill at medica-
tion initiation, they were not found to differ from SSRI initiators on outpatient and 
inpatient service use for MDD in the year following medication initiation.
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objeCtives: Antidepressants use is increasing worldwide but is particularly high 
in Belgium compared to other EU countries whereas suicide-rates in Belgium are 
among the highest. This could reflect misuse of antidepressants resulting in an 
important economic burden. The latter is part of a separate abstract. This study 
assesses the prescribing patterns of antidepressants in Belgium and whether there 
is misuse or not. Methods: Given the efforts to deinstitutionalize mental health 
services, primary care plays now an important role in the diagnosis and treatment 
of mild to moderate mental health disorders. As such, patients treated in 2014 that 
had no prescription with antidepressants in 2013 were analysed from the IMS Health 
Longitudinal Patients Database (IMS Health LPD). The reasons for antidepressant 
prescription and the treatment duration were assessed. The IMS Health LPD, in 
Belgium collects information on diagnosis and prescriptions of a set of 360 general 
practitioners covering about 300,000 patients. Data is collected through an office-
based Electronic Medical Records software. Results: IMS Health LPD showed that 
60% of patients taking antidepressants receive it for depression. The next most 
frequent diagnosis was sleeping disorders (17%) and anxiety (7.5%). Moreover, of 
the patients with depression, 16% received only 1 prescription of an antidepressant 
covering at maximum a month of treatment. This can be considered insufficient 
given the mode of action of these drugs (treatment effect only starts after three 
weeks). ConClusions: Real world data on Belgian antidepressants prescription 
clearly shows that antidepressants are used outside the generally accepted indica-
tions and, when used in the correct indication for a too short time period. By improv-
ing prescribing patterns of antidepressants mental health indicators might improve.
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objeCtives: Antidepressants use is increasing worldwide but is particularly high 
in Belgium compared to other EU countries whereas suicide-rates in Belgium are 
among the highest. This could reflect misuse of antidepressants resulting in an 
important economic burden. The former is part of a separate abstract. The aim 
here was to evaluate potential savings that could be realized in case prescrip-
tions behavior in Belgium would be similar to neighbor countries. Methods: 
Current spending levels for antidepressants and mood stabilizer prescriptions 
were determined in Belgium, France and the Netherlands. Volume and value sales 
were determined per country (average number of pills sold/capita) based on IMS 
Health Belgian National Retail Database available to IMS Health in both countries 
via the IMS MIDAS platform (2013 data). The potential country-level prescription 
cost in Belgium was estimated by multiplying average number of pills/person 
in France and the Netherlands, with the cost/pill in Belgium and extrapolating 
the result to the total population in Belgium, assuming that prescribing levels in 
Belgium were equal to those in France and the Netherlands and using Belgian 
prices. Results: In Belgium the number of pills per capita is respectively 45% 
and 48% higher compared to France and the Netherlands (34.17 vs. 23.62 vs. 23.15 
pills/person). With a 30% smaller population than the Netherlands, spending in 
Belgium is 4 times higher. In France, having a 6 times larger population compared 
to Belgium, spending is only 3 times higher. The estimated savings for the Belgian 
payer applying the usage (pill/person) of respectively France and the Netherlands 
and current cost/pill in Belgium were € 67 and € 70 Mn, meaning around 30% of 
current spending in Belgium. ConClusions: By comparing Belgium’s prescrip-
tion patterns to France and the Netherlands, we estimated important potential 
savings due to antidepressant mis-use/over-use that could be re-invested in for 
example mental health prevention.
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objeCtives: Depression is the most common psychiatric disease in the world that 
has a reactive environmental character, where the atmosphere can provide this 
disease. The objective of this study was to identify the types of drug treatments 
for depression, in 2014, with data from the health insurance of Brazil. Methods: 
The patients were identified through the health insurance database of Brazil, 
from January to December 2014, who bought some antidepressants medication 
in the analyzed period. From the date of the purchase, it was possible to obtain 
a methodology capable of identifying the age of these patients and the main 
molecules used for the treatment. Results: From a total of 884.143 patients who 
used any type of antidepressant, it was found that 85 % of these patients used the 
following molecules: Fluoxetine (19.0%), Sertraline (18.6%), Escitalopram (14.1%), 
Paroxetine (12.8 %), Bupropion (11.1%) and Amitriptyline (9.5%). Considering the 
age of these patients it was identified that from the age of 30, the incidence in the 
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objeCtives: The objective of the study is to provide utilization data for lisdexam-
fetamine dimesylate (LDX) following its launch in 2013 in Europe for treatment of 
attention deficit hyperactivity disease (ADHD). Methods: This is a multi-country 
drug utilization study using database analysis. Longitudinal EMR databases (Disease 
Analyzer, Germany and CPRD, United Kingdom), National Registries (Denmark, 
Sweden), prescription databases using pharmacy retail data (IFAK/New Index, 
Switzerland) and cross-sectional databases (Prescribing Insights Spain, Switzerland) 
were used. The study includes all patients in the databases who have been pre-
scribed LDX at least once during the study period (March [first EU launch] 2013 – 
December 2014). Results: The majority of patients treated with LDX were males 
in all six European countries studied: Germany (84% in Paediatrician Panel, 78% in 
Neurology/Psychiatry panel), UK (82%), Spain (87%), Denmark (63%), Sweden (60%) 
and Switzerland (75%). Less than 1% of all patients were < 6 years in all countries 
studied. The proportion of patients treated with LDX > 18 years of age was estimated 
to be 12% in Germany (Neurology/Psychiatry Panel Germany), 12% in the UK (CPRD), 
45% in Denmark, 60% in Sweden and 70% in Switzerland. Prescribed average daily 
dose (ADD) of LDX was within the recommended range (30-70mg) for 97% to 100% of 
the patients, with a mean ADD of 44mg in Germany, 48mg in UK and about 44mg in 
Sweden. In Denmark and Switzerland, the recommended dose was not recorded on 
the prescription. ConClusions: Overall, the findings indicate that LDX is mainly 
prescribed within the EMA-approved Summary of Product Characteristics with 
regard to the indicated patients and dose regimen. Adult use is more common in 
Switzerland where use of LDX was already licensed for adults in 2014, or in Denmark 
and Sweden where use of LDX is indicated for adults as of 2015. Prescribed use in 
patients less than 6 years is ≤ 1%.
PMH46
AnTidePressAnT use in PATienTs wiTH MAjor dePressive disorder:  
A coMPArison of TreATMenT resisTAnT And non-TreATMenT resisTAnT 
ePisodes in THe uniTed KingdoM using THe cPrd dATABAse
Kubitz N1, Potluri R2, Mehra M3
1Janssen-Cilag GmbH, Neuss, Germany, 2SmartAnalyst Inc., New York, NY, USA, 3Global Market 
Access & Commercial Strategy Organization, Raritan, NJ, USA
objeCtives: A subset of patients with Major Depressive Disorder (MDD) who are 
treated with, but do not respond to antidepressant and/or antipsychotic (ADAP) 
drugs/ mood stabilizers are characterized as progressing to treatment resistant 
depression (TRD). This study characterized TRD and non-TRD episodes among 
MDD patients in the UK Clinical Practice Research Datalink (CPRD) during 2000-
2012. Methods: Business rules centered on diagnosis and use of antidepressants 
were used to identify new MDD episodes. Treatment regimens were defined as 
mono- or combination therapy with concurrently administered ADAP drugs. TRD 
was defined as ≥ 2 distinct failed regimens in an episode. Adults 18 to 65 years of 
age were included. Results: Of the 427,467 MDD patients, 291,388 (68.2%) were 
excluded because they lacked an index diagnosis date, met an exclusion diagno-
sis criterion, did not meet the age criteria, or had missing age or gender; 136,079 
patients (31.8%) were retained. A total of 6,311 (5.1%) distinct episodes with ≥ 1 ADAP 
prescription were treatment-resistant, with 6,221 (5.9%) of all patients experienc-
ing ≥ 1 TRD episode. Median time to developing TRD was < 11 months (307 days). 
Mean duration of a TRD episode was 1,239 days versus only 305 days for non-TRD 
episodes. Nearly half (46%) of all TRD episodes had up to 4 lines of treatment (LOTs); 
in contrast, only 19% of non-TRD episodes with ≥ 1 ADAP prescription had > 1 LOT. 
Use of combination drug regimens was seen in 46.6% of TRD episodes compared 
with 12.8% of drug-treated non-TRD episodes. TRD episodes were associated with 
higher electroconvulsive therapy exposure, more psychiatrist visits and behavioral 
therapy sessions versus non-TRD episodes. More TRD patients suffered from co-
morbidities such as anxiety and panic disorder. ConClusions: This analysis of 
data from the largest provider of health care in the UK highlights the significant 
burden of TRD on patients and providers.
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objeCtives: To compare baseline characteristics and major depressive disorder 
(MDD)-related healthcare resource use during the 1-year post-medication initia-
tion of patients with MDD who were initiated on selective-noradrenaline-reup-
take inhibitor (SNRI) compared to selective-serotonin-reuptake inhibitor (SSRI) in 
Beijing. Methods: Data from the Beijing Urban Employee Basic Medical Insurance 
Database from July 1, 2011-December 31, 2013, were used. Patients diagnosed with 
MDD were identified using ICD-10th F32/F33. The first-diagnosis date in 2012 was 
designated as the index date. Patients were aged ≥ 18 years; without comorbid can-
cer, schizophrenia, or bipolar disorder; and with 12-months continuous enrollment. 
Logistic regression with stepwise-effect-selection method and multivariate analy-
ses were performed. Results: A total of 4769 patients were included, with 8.6% 
initiated on SNRI. Compared with SSRI initiators, SNRI initiators were more likely 
to be treated at mental than general hospitals (Odds ratio (OR) [95% confidence 
interval (CI)]: 1.96[1.58, 2.42]), had more MDD-related outpatient visits during the 
6-month pre-index date (1.18[1.11, 1.25]), and were more likely to be treated at 
tier-3 hospitals (0.15[0.06, 0.41] for tier 1 vs 3; 0.50[0.36, 0.69] for tier 2 vs 3). In the 
year following medication initiation, few patients (0.5%) experienced MDD-related 
hospitalizations in either medication initiation group. The SNRI and SSRI initiators 
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A415
people with psoriasis. Methods: We used the Taiwan’s National Health Insurance 
Research Database to conduct a nationwide population-based cohort study to assess 
the risk of incident CKD and ESRD in people with psoriasis and to further evalu-
ate the respective risk estimates in those with mild and severe psoriasis based 
on treatment patterns. Results: A total of 4,633 psoriatic patients and 922,534 
nonpsoriatic controls were included. Severe psoriasis, but not mild psoriasis, was 
an independent risk factor of incident CKD and ESRD (adjusted hazard ratio being 
1.90 (95% confidence interval 1.33-2.70) and 2.97 (95% confidence interval 1.72-
5.11), respectively) after adjustment for potential confounders including age, gender, 
comorbidities, and used of nonsteroidal anti-inflammatory drugs (NSAIDs). Severe 
psoriasis remained an independent risk factor of incident CKD and ESRD after vari-
ous sensitivity analyses after adjusting for the presence of osteoarthritis and/or 
rheumatoid arthritis, use of methotrexate and/or cyclosporine, and chronic use 
of NSAIDs for at least 2 months. Psoriatic arthritis was an effect modifier for CKD 
and ESRD. ConClusions: The associations of severe psoriasis with CKD and ESRD 
should be recognized. Assessment of renal function and avoidance of long-term 
use of nephrotoxic drugs shall be implemented in the integrative care for patients 
with severe psoriasis.
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objeCtives: To assess co-morbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization (MRU) in patients suffering from glaucoma in 
Brazil. Methods: Patients self-reported data were collected from 2011-2012 
National Health and Wellness Survey (NHWS -Kantar Health global self-reported 
general population survey in healthcare). QOL was measured by the physical com-
ponent score (PCS) and mental component core (MCS)of the Short Form-12 (SF-12) 
(mean score of 50 for general population). Loss of work/productivity was measured 
by the validated Work Productivity and Activity Impairment (WPAI) instrument. 
MRU was measured by healthcare provider, emergency room (ER) visits and hospi-
talization in the past 6 months.Comparisons were made between respondents who 
were diagnosed with glaucoma vs. respondents without glaucoma (non-glaucoma 
group). Since glaucoma typically affects the adult population, respondents with an 
age of 35 and above were included in the analysis. Results: Among 24,000 survey 
respondents, 242 (1.0%)respondents were diagnosed with glaucoma. The average age 
in the glaucoma group was 53.5 years and 48.2% were male compared to the non-
glaucoma group where average age was 51.6 years with 47.8% male. The Glaucoma 
group reported more co-morbidities, lower mean PCS scores (46.3 vs. 49.4) and MCS 
scores (45.6 vs. 49.0), more healthcare providers visits (93.7%vs.77.4%), ER visits 
(29.6%vs19.0%) and hospitalizations (17.5%vs.9.7%) in the past 6 months compared 
to non-glaucoma group. Also, the glaucoma group reported 36.5% work/productiv-
ity loss (absenteeism and presenteeism) and 33.5% impairments in daily activity 
compared to 17.5% and 22.1% in non-glaucoma group. All comparisons in QOL, 
MRU, and work/productivity loss between two groups were statistically significant 
at P< 0.05. ConClusions: From the Brazil NHWS results, glaucoma patients suffer 
from impairments in quality of life, work/productivity loss,more co-morbidities 
and use of medical services. Findings indicate that glaucoma can have a statistical 
significant impact and negative impact on QOL, MRU and work productivity for 
patients suffering from the disease and for the healthcare system.
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objeCtives: Worldwide, glaucoma is the second highest cause of blindness. 
Surgery is the treatment of choice when medications fail to control intraocu-
lar pressure (IOP). This systematic literature review and meta-analysis aimed to 
compare efficacy and safety of the common surgical options available for pri-
mary angle closure glaucoma (PACG). Methods: Studies with PACG patients 
who underwent trabeculectomy, phacotrabeculectomy or phacoemulsification 
were screened and included from electronic databases. The outcomes compared 
were IOP (24 months), postoperative angle opening distance (AOD), postoperative 
trabecular-ciliary process distance, postoperative anterior chamber depth (ACD), 
synechial angle closure all at 1 year, best corrected visual acuity (BCVA) at 1 year 
and 2 years, and intra- and post-operative complications of the surgery like worse 
logarithmic minimal angle resolution BCVA, progression of glaucomatous optic 
neuropathy, progression of glaucomatous visual field at 2 years. Critical appraisal 
of studies was carried out using Cochrane’s Risk of Bias tool. Meta-analysis of 
clinical trials was conducted using RevMan v5.1, through pooling of medically 
controlled and uncontrolled glaucoma patients where available. Results: Of the 
704 studies that were screened, five randomised clinical trials were included. 
Pooled analysis of two studies showed IOP at 24 months was better controlled by 
phacotrabeculectomy (mean difference 1.46 [95%CI 0.24,2.67]). Post-operative AOD 
and ACD results favoured phacoemulsification (mean difference 123.60 [95%CI 
51.46,195.74] and 230.60 [95%CI 106.30,354.90] respectively). The post-operative 
complications showed risk ratio of 0.07 (95%CI 0.01,0.34) showing fewer com-
plications in phacoemulsification patients. The remaining outcomes showed no 
significant results. Phacoemulsification had significantly lesser complications 
than trabeculectomy, with risk ratio of 0.08 (95%CI 0.01,0.60). The analyses of the 
observational and economic studies are being carried out, the results of which will 
be included in the poster. ConClusions: The results show that while phacotrab-
eculectomy has better IOP control than phacoemulsification, the latter has higher 
safety than both phacotrabeculectomy and trabeculectomy.
use of these drugs increases by 18.0%, Fluoxetine is responsible for the growth 
of 88.5 % in this incidence, with a confidence interval of 95 % and standard error 
of 2%. ConClusions: It was identified that the main molecule used for depres-
sion, in the sample analyzed, was fluoxetine and the age with higher incidence of 
purchases of these drugs is between 20 and 50 years. As WHO data (World Health 
Organization), depression will be the most common disease in the world in 2030. 
The relationship between doctor and patient has a fundamental importance in 
successful treatment. Thus, the patient monitoring is extremely important to con-
trol the disease in the country.
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objeCtives: mental disorders are a significant problem of public health, espe-
cially for disability they generate during adulthood. They strongly influence qual-
ity of life for patients as well as having important impacts on society and mental 
health services, creating a significant economic problem for the health system 
and for patient. Methods: an integrated clinical pathway (PDTA) for patient with 
schizophrenia has been validated by a group of Italian medical experts. This clinical 
governance tool, enables to organize and integrate activities and interventions in 
a context where, several specialties, professions and areas of action (hospital and 
territorial care) are involved. Results: drug acquisition costs are not the highest 
costs in the schizophrenia management. The highest costs are related to: frequent 
hospitalization, residential care costs, loss of individuals productivity, high costs 
for caregiver. The aim of our work is to offer, to the different actors involved in 
the schizophrenia treatment management, a governance tool (PDTA) that allow: to 
manage the treatment variability, to monitor the resource utilization, to monitor the 
adherence and to improve the quality of processes and outcomes. Also the schizo-
phrenia PDTA, promoting the early use of antipsychotics LAI, answer to the main 
unmet needs in the pathology management: the frequent relapses, the functional 
status preservation and the maintenance of good quality of life. An indicators set 
was validated to monitor the correct adoption of PDTA in order to generate savings 
and better manage the cost of disease. ConClusions: thanks to integrated clinical 
pathway all the actors involved in treating mental disorders are able to outline, the 
best clinical pathway practicable, compared to schizophrenia, in order to optimize 
resources and costs. A desirable perspective is the adoption of the clinical pathway 
at the regional level and in the future also at the national level.
sensory sysTeMs disorders – clinical outcomes studies
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objeCtives: To evaluate safety and efficacy of Timolol and Brimolol 
(Brimonidine+Timolol) and study effect of aerobic exercise on intra ocular ten-
sion (IOT) in timolol treated patients. Methods: A prospective study including 90 
cases of newly diagnosed primary open angle glaucoma (POAG) from ophthalmology 
inpatients divided into 3 groups: 1-Timolol, 2-Timolol (Exercise) and 3-Brimolol.Each 
patient was administered with topical drugs followed up every 15th day. Efficacy of 
drugs were tested based on IOT measurement by Non-contact tonometer at an inter-
val of 15 days and safety on the basis of ADR check list, fundoscopy and slit lamp 
examination with tear film break up time and tear gland secretion (schirmer test).
In group 2, patients were advised to do 30 min exercise daily for 1 month. Results: 
Mean reduction in IOT was statistically significant with values as 2.7, 5& 7.9 mmHg 
and 6, 9&11 mmHg in group 1, 2 and 3 at 15th and 30th day. Frequency of ADR in 
group 1, 2&3 was 36%, 30% &40% respectively with the most frequent ADR in group 
1&2 as burning of eyes (50%) & in group 3 as dryness (22%).Effect of brimolol on 
schirmer test was significant with a mean difference of 4.33 mmHg. Frequency of 
patients missing ophthalmic doses were 60%, 48% &48% and drop out treatment 
rate was 9%,9%& 14% in group 1, 2& 3 respectively with monetary reason (most com-
mon).Most frequent cause of missing ophthalmic doses was ADR (30%) in group 1&2 
and monetary reason (43%) in group 3(predominantly in lower class).GQR-15 score 
was 35, 29&30.5 in group 1, 2 &3. ConClusions: Brimolol provides superior IOT 
lowering to timolol but is less well tolerated.Exercise along with timolol provides 
superior IOT lowering effect to timolol alone & is better tolerated, has superior visual 
QOL with reduced frequency of missed ophthalmic doses.Brimolol substantially 
reduces tear gland secretion.
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objeCtives: Psoriasis is a chronic inflammatory dermatosis that has been associ-
ated with various cardiovascular and metabolic comorbidities, including myocardial 
infarction, stroke, and diabetes mellitus. Recently, there are studies reporting the 
association of psoriasis with renal diseases. This study aimed to evaluate the risk 
of incident chronic kidney disease (CKD) and end-stage renal disease (ESRD) in 
